{"id":5168,"date":"2012-03-05T09:00:00","date_gmt":"2012-03-05T09:00:00","guid":{"rendered":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/onderzoek-naar-liraglutide\/"},"modified":"2024-09-23T11:22:46","modified_gmt":"2024-09-23T11:22:46","slug":"onderzoek-naar-liraglutide","status":"publish","type":"post","link":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/onderzoek-naar-liraglutide\/","title":{"rendered":"Onderzoek naar liraglutide"},"content":{"rendered":"Onderzoekers van de University of Buffalo starten een vervolg-onderzoek naar de effectiviteit van het middel liraglutide bij T1D. De werkzaamheid van liraglutide bij T2D is al onderzocht en lijkt te berusten op verhogen van de insuline productie in de alvleesklier. OP grond daarvan werd aangenomen dat het middel bij T1D niet erg effectief zou zijn, omdat daar het insulineproducerend vermogen grotendeels verloren is gegaan. In een verkennend onderzoek is echter gebleken dat het wel degelijk effecten heeft bij T1D, namelijk een snelle en belangrijke vermindering van de bloedsuiker schommelingen en dus ook in een reductie in de hoeveelheid insuline die pati\u00ebnten moesten nemen. Ook was er een gemiddeld gewichtsverlies van 4,5 kilo. Vermoed wordt dat liraglutide de productie van glucagon onderdrukt. Glucagon verhoogt de bloedsuiker spiegel.\n<div><a href=\"http:\/\/www.physorg.com\/wire-news\/91780929\/could-type-2-diabetes-drug-benefit-teen-and-young-adult-type-1-d.html\">Lees verder (Engelstalig)<\/a><\/div>","protected":false,"raw":""},"excerpt":{"rendered":"<p>Onderzoekers van de University of Buffalo starten een vervolg-onderzoek naar de effectiviteit van het middel liraglutide bij T1D. De werkzaamheid van liraglutide bij T2D is al onderzocht en lijkt te berusten op verhogen van de insuline productie in de alvleesklier. OP grond daarvan werd aangenomen dat het middel bij T1D niet erg effectief zou zijn, [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[184,187],"tags":[],"class_list":["post-5168","post","type-post","status-publish","format-standard","hentry","category-archief","category-behandelen"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Onderzoek naar liraglutide - Breakthrough T1D<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/onderzoek-naar-liraglutide\/\" \/>\n<meta property=\"og:locale\" content=\"nl_NL\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Onderzoek naar liraglutide - Breakthrough T1D\" \/>\n<meta property=\"og:description\" content=\"Onderzoekers van de University of Buffalo starten een vervolg-onderzoek naar de effectiviteit van het middel liraglutide bij T1D. De werkzaamheid van liraglutide bij T2D is al onderzocht en lijkt te berusten op verhogen van de insuline productie in de alvleesklier. OP grond daarvan werd aangenomen dat het middel bij T1D niet erg effectief zou zijn, [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/onderzoek-naar-liraglutide\/\" \/>\n<meta property=\"og:site_name\" content=\"Breakthrough T1D\" \/>\n<meta property=\"article:published_time\" content=\"2012-03-05T09:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-09-23T11:22:46+00:00\" \/>\n<meta name=\"author\" content=\"ylt-admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Geschreven door\" \/>\n\t<meta name=\"twitter:data1\" content=\"ylt-admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Geschatte leestijd\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minuut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/breakthrought1d.eu\\\/nl\\\/nieuws\\\/onderzoek-naar-liraglutide\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/breakthrought1d.eu\\\/nl\\\/nieuws\\\/onderzoek-naar-liraglutide\\\/\"},\"author\":{\"name\":\"ylt-admin\",\"@id\":\"https:\\\/\\\/breakthrought1d.eu\\\/nl\\\/#\\\/schema\\\/person\\\/c141fde9814deb17e9eb392bdb6619a6\"},\"headline\":\"Onderzoek naar liraglutide\",\"datePublished\":\"2012-03-05T09:00:00+00:00\",\"dateModified\":\"2024-09-23T11:22:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/breakthrought1d.eu\\\/nl\\\/nieuws\\\/onderzoek-naar-liraglutide\\\/\"},\"wordCount\":136,\"publisher\":{\"@id\":\"https:\\\/\\\/breakthrought1d.eu\\\/nl\\\/#organization\"},\"articleSection\":[\"Archief\",\"Behandelen\"],\"inLanguage\":\"nl-NL\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/breakthrought1d.eu\\\/nl\\\/nieuws\\\/onderzoek-naar-liraglutide\\\/\",\"url\":\"https:\\\/\\\/breakthrought1d.eu\\\/nl\\\/nieuws\\\/onderzoek-naar-liraglutide\\\/\",\"name\":\"Onderzoek naar liraglutide - Breakthrough T1D\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/breakthrought1d.eu\\\/nl\\\/#website\"},\"datePublished\":\"2012-03-05T09:00:00+00:00\",\"dateModified\":\"2024-09-23T11:22:46+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/breakthrought1d.eu\\\/nl\\\/nieuws\\\/onderzoek-naar-liraglutide\\\/#breadcrumb\"},\"inLanguage\":\"nl-NL\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/breakthrought1d.eu\\\/nl\\\/nieuws\\\/onderzoek-naar-liraglutide\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/breakthrought1d.eu\\\/nl\\\/nieuws\\\/onderzoek-naar-liraglutide\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/breakthrought1d.eu\\\/nl\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Onderzoek naar liraglutide\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/breakthrought1d.eu\\\/nl\\\/#website\",\"url\":\"https:\\\/\\\/breakthrought1d.eu\\\/nl\\\/\",\"name\":\"Breakthrough T1D\",\"description\":\"Wij zetten ons in voor een toekomst zonder T1D\",\"publisher\":{\"@id\":\"https:\\\/\\\/breakthrought1d.eu\\\/nl\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/breakthrought1d.eu\\\/nl\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"nl-NL\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/breakthrought1d.eu\\\/nl\\\/#organization\",\"name\":\"Breakthrough T1D\",\"url\":\"https:\\\/\\\/breakthrought1d.eu\\\/nl\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\\\/\\\/breakthrought1d.eu\\\/nl\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/breakthrought1d.eu\\\/nl\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/BTlogo.png\",\"contentUrl\":\"https:\\\/\\\/breakthrought1d.eu\\\/nl\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/BTlogo.png\",\"width\":330,\"height\":141,\"caption\":\"Breakthrough T1D\"},\"image\":{\"@id\":\"https:\\\/\\\/breakthrought1d.eu\\\/nl\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/breakthrought1d.eu\\\/nl\\\/#\\\/schema\\\/person\\\/c141fde9814deb17e9eb392bdb6619a6\",\"name\":\"ylt-admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/67a3317a8082bc0f586c2e46f82a1617530cf674f2027a1a7d60fdff63a2c3e8?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/67a3317a8082bc0f586c2e46f82a1617530cf674f2027a1a7d60fdff63a2c3e8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/67a3317a8082bc0f586c2e46f82a1617530cf674f2027a1a7d60fdff63a2c3e8?s=96&d=mm&r=g\",\"caption\":\"ylt-admin\"},\"sameAs\":[\"https:\\\/\\\/87.250.144.92\"],\"url\":\"https:\\\/\\\/breakthrought1d.eu\\\/nl\\\/nieuws\\\/author\\\/ylt-admin\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Onderzoek naar liraglutide - Breakthrough T1D","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/onderzoek-naar-liraglutide\/","og_locale":"nl_NL","og_type":"article","og_title":"Onderzoek naar liraglutide - Breakthrough T1D","og_description":"Onderzoekers van de University of Buffalo starten een vervolg-onderzoek naar de effectiviteit van het middel liraglutide bij T1D. De werkzaamheid van liraglutide bij T2D is al onderzocht en lijkt te berusten op verhogen van de insuline productie in de alvleesklier. OP grond daarvan werd aangenomen dat het middel bij T1D niet erg effectief zou zijn, [&hellip;]","og_url":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/onderzoek-naar-liraglutide\/","og_site_name":"Breakthrough T1D","article_published_time":"2012-03-05T09:00:00+00:00","article_modified_time":"2024-09-23T11:22:46+00:00","author":"ylt-admin","twitter_card":"summary_large_image","twitter_misc":{"Geschreven door":"ylt-admin","Geschatte leestijd":"1 minuut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/onderzoek-naar-liraglutide\/#article","isPartOf":{"@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/onderzoek-naar-liraglutide\/"},"author":{"name":"ylt-admin","@id":"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/c141fde9814deb17e9eb392bdb6619a6"},"headline":"Onderzoek naar liraglutide","datePublished":"2012-03-05T09:00:00+00:00","dateModified":"2024-09-23T11:22:46+00:00","mainEntityOfPage":{"@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/onderzoek-naar-liraglutide\/"},"wordCount":136,"publisher":{"@id":"https:\/\/breakthrought1d.eu\/nl\/#organization"},"articleSection":["Archief","Behandelen"],"inLanguage":"nl-NL"},{"@type":"WebPage","@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/onderzoek-naar-liraglutide\/","url":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/onderzoek-naar-liraglutide\/","name":"Onderzoek naar liraglutide - Breakthrough T1D","isPartOf":{"@id":"https:\/\/breakthrought1d.eu\/nl\/#website"},"datePublished":"2012-03-05T09:00:00+00:00","dateModified":"2024-09-23T11:22:46+00:00","breadcrumb":{"@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/onderzoek-naar-liraglutide\/#breadcrumb"},"inLanguage":"nl-NL","potentialAction":[{"@type":"ReadAction","target":["https:\/\/breakthrought1d.eu\/nl\/nieuws\/onderzoek-naar-liraglutide\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/onderzoek-naar-liraglutide\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/breakthrought1d.eu\/nl\/"},{"@type":"ListItem","position":2,"name":"Onderzoek naar liraglutide"}]},{"@type":"WebSite","@id":"https:\/\/breakthrought1d.eu\/nl\/#website","url":"https:\/\/breakthrought1d.eu\/nl\/","name":"Breakthrough T1D","description":"Wij zetten ons in voor een toekomst zonder T1D","publisher":{"@id":"https:\/\/breakthrought1d.eu\/nl\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/breakthrought1d.eu\/nl\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"nl-NL"},{"@type":"Organization","@id":"https:\/\/breakthrought1d.eu\/nl\/#organization","name":"Breakthrough T1D","url":"https:\/\/breakthrought1d.eu\/nl\/","logo":{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/logo\/image\/","url":"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2024\/11\/BTlogo.png","contentUrl":"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2024\/11\/BTlogo.png","width":330,"height":141,"caption":"Breakthrough T1D"},"image":{"@id":"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/c141fde9814deb17e9eb392bdb6619a6","name":"ylt-admin","image":{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/secure.gravatar.com\/avatar\/67a3317a8082bc0f586c2e46f82a1617530cf674f2027a1a7d60fdff63a2c3e8?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/67a3317a8082bc0f586c2e46f82a1617530cf674f2027a1a7d60fdff63a2c3e8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/67a3317a8082bc0f586c2e46f82a1617530cf674f2027a1a7d60fdff63a2c3e8?s=96&d=mm&r=g","caption":"ylt-admin"},"sameAs":["https:\/\/87.250.144.92"],"url":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/author\/ylt-admin\/"}]}},"_links":{"self":[{"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/posts\/5168","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/comments?post=5168"}],"version-history":[{"count":1,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/posts\/5168\/revisions"}],"predecessor-version":[{"id":7325,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/posts\/5168\/revisions\/7325"}],"wp:attachment":[{"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/media?parent=5168"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/categories?post=5168"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/tags?post=5168"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}